CALVIRI Revenue and Competitors
Estimated Revenue & Valuation
- CALVIRI's estimated annual revenue is currently $1.8M per year.
- CALVIRI's estimated revenue per employee is $77,500
- CALVIRI's total funding is $9.3M.
Employee Data
- CALVIRI has 23 Employees.
- CALVIRI grew their employee count by 10% last year.
CALVIRI's People
Name | Title | Email/Phone |
---|---|---|
1 | Founding CEO | Reveal Email/Phone |
2 | VP Research & Product Development | Reveal Email/Phone |
3 | Executive Assistant & Office Manager | Reveal Email/Phone |
4 | Manufacturing Manager | Reveal Email/Phone |
5 | Senior Research Technician | Reveal Email/Phone |
6 | Senior Mechatronics Engineer | Reveal Email/Phone |
7 | Founding CEO, Chairman BOD | Reveal Email/Phone |
8 | Visiting Graduate Student | Reveal Email/Phone |
CALVIRI Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 4 | 0% | N/A | N/A |
#2 | $0.9M | 5 | 0% | N/A | N/A |
#3 | $0.8M | 4 | 0% | N/A | N/A |
#4 | $5.3M | 34 | 0% | N/A | N/A |
#5 | $2.5M | 12 | -8% | N/A | N/A |
#6 | $1.1M | 6 | 0% | N/A | N/A |
#7 | $0.9M | 5 | 0% | N/A | N/A |
#8 | $2.2M | 29 | 21% | $58.2M | N/A |
#9 | $171.9M | 1109 | -3% | N/A | N/A |
#10 | $0.9M | 5 | 0% | N/A | N/A |
What Is CALVIRI?
Calviri's mission is to provide affordable products worldwide that will end deaths from cancer by combining a unique, highly immunogenic source of neoantigens with a peptide array platform. On our course to eradicate cancer we will develop new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting.
keywords:N/A$9.3M
Total Funding
23
Number of Employees
$1.8M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.2M | 23 | 21% | N/A |
#2 | $2M | 23 | 0% | N/A |
#3 | $6M | 23 | 15% | N/A |
#4 | $5.2M | 23 | -12% | N/A |
#5 | N/A | 23 | -4% | N/A |